| 000 | 01635 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250517001239.0 | ||
| 264 | 0 | _c20150126 | |
| 008 | 201501s 0 0 eng d | ||
| 022 | _a1532-1827 | ||
| 024 | 7 |
_a10.1038/bjc.2014.534 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSathe, A | |
| 245 | 0 | 0 |
_aMutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy. _h[electronic resource] |
| 260 |
_bBritish journal of cancer _cNov 2014 |
||
| 300 |
_a2103-13 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aApoptosis _xdrug effects |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 | _aChickens |
| 650 | 0 | 4 | _aChorioallantoic Membrane |
| 650 | 0 | 4 | _aClass I Phosphatidylinositol 3-Kinases |
| 650 | 0 | 4 |
_aDual Specificity Phosphatase 1 _xphysiology |
| 650 | 0 | 4 |
_aExtracellular Signal-Regulated MAP Kinases _xmetabolism |
| 650 | 0 | 4 |
_aHeterocyclic Compounds, 3-Ring _xpharmacology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMolecular Targeted Therapy |
| 650 | 0 | 4 | _aMutation |
| 650 | 0 | 4 |
_aPhosphatidylinositol 3-Kinases _xgenetics |
| 650 | 0 | 4 | _aPhosphorylation |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins c-akt _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aUrinary Bladder Neoplasms _xdrug therapy |
| 700 | 1 | _aGuerth, F | |
| 700 | 1 | _aCronauer, M V | |
| 700 | 1 | _aHeck, M M | |
| 700 | 1 | _aThalgott, M | |
| 700 | 1 | _aGschwend, J E | |
| 700 | 1 | _aRetz, M | |
| 700 | 1 | _aNawroth, R | |
| 773 | 0 |
_tBritish journal of cancer _gvol. 111 _gno. 11 _gp. 2103-13 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/bjc.2014.534 _zAvailable from publisher's website |
| 999 |
_c24310504 _d24310504 |
||